Archive for 09/22/12

<h2 class="subheadline">
Nutra Pharma Announces the Direct Distribution 
of Their Nyloxin(TM) Line of Pain Relievers Through TCN, a Network of 
Distributors in More Than 20 Countries</h2>
<h2 class="subheadline">
 Companies:</h2>
<div class="yom-mod yom-mod yom-article-tags clearfix">
<div class="bd">
<ul class="clearfix related">
<li class="first last"><a href="http://finance.yahoo.com/q?s=nphc">Nutra Pharma Corporation</a></li>
</ul>
</div>
</div>
<div class="yog-col yog-5u">
<div class="yom-mod yom-accordion-table" id="mediarelatedquotes" style="height: 208.933px;">
<div class="hd">
<h3>
RELATED QUOTES</h3>
</div>
<div class="bd">
<table class="yui3-accordion" id="yui_3_5_1_1_1348381831051_801"><thead id="yui_3_5_1_1_1348381831051_936">
<tr id="yui_3_5_1_1_1348381831051_935"><th class="first" id="yui_3_5_1_1_1348381831051_945">Symbol</th><th id="yui_3_5_1_1_1348381831051_938">Price</th><th id="yui_3_5_1_1_1348381831051_934">Change</th></tr>
</thead><tbody id="yui_3_5_1_1_1348381831051_932">
<tr class="yui3-accordion-item yui3-accordion-item-hd yui3-accordion-item-trigger yui3-accordion-item-active" id="yui_3_5_1_1_1348381831051_803"><td class="first" id="yui_3_5_1_1_1348381831051_943"><span class="symbol"><a href="http://finance.yahoo.com/q?s=nphc">NPHC</a></span></td><td id="yui_3_5_1_1_1348381831051_940"><span class="streaming-datum" id="yfs_l84_nphc">0.0157</span></td><td><span class="streaming-datum yfi-price-change-red" id="yfs_c63_nphc"><span class="yfi-price-change-green">+0.0008</span></span></td></tr>
<tr class="yui3-accordion-item-bd yui3-accordion-item-bd-active" id="yui_3_5_1_1_1348381831051_931"><td colspan="3" id="yui_3_5_1_1_1348381831051_930"><div id="yui_3_5_1_1_1348381831051_929">
<a href="http://finance.yahoo.com/q?s=nphc" id="yui_3_5_1_1_1348381831051_928"><img alt="" id="yui_3_5_1_1_1348381831051_933" src="http://ichart.finance.yahoo.com/t?s=nphc&lang=en-US&region=US" title="" /></a></div>
</td></tr>
</tbody></table>
</div>
</div>
</div>
<div class="first">
CORAL
 SPRINGS, Fla., Sept. 21, 2012 (GLOBE NEWSWIRE) -- Nutra Pharma 
Corporation (Pink Sheets:NPHC), a biotechnology company that is 
developing treatments for Multiple Sclerosis (MS), Human 
Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, 
announced today that they have begun selling Nyloxin through the TCN 
group of direct distributors.</div>
"We are excited to be working with TCN to aggressively market and sell Nyloxin," explained Rik J Deitsch, Chairman and CEO of <a href="http://www.globenewswire.com/newsroom/ctr?d=10005898&l=2&a=Nutra%20Pharma%20Corporation&u=http%3A%2F%2Fwww.nutrapharma.com%2F">Nutra Pharma Corporation</a>.
 "TCN distributors have been working with us over the past few months to
 roll out Nyloxin to approximately 40,000 distributors in the United 
States and almost 400,000 distributors globally," he concluded.<br />

<a href="http://www.globenewswire.com/newsroom/ctr?d=10005898&l=3&a=Nyloxin&u=http%3A%2F%2Fwww.nyloxin.com%2F">Nyloxin</a>(TM)
 is an over-the-counter (OTC) pain reliever clinically proven to treat 
moderate to severe (Stage 2) chronic pain. Nyloxin(TM) is currently 
available in the United States as an oral spray for treating back pain, 
neck aches, headaches, joint pain, migraines, and neuralgia, and as a 
topical gel for treating joint pain, neck pain, arthritis pain, and pain
 from repetitive stress. In addition to its everyday strength 
formulation, Nyloxin(TM) is also offered in an extra strength formula 
for more advanced, Stage 3, chronic pain.<br />

"The Nyloxin products represent a wonderful opportunity for our 
distributors," commented Dalton Johnson, CEO of TCN. "These are 
pain-relievers and anti-inflammatory drugs that have provided great 
results with almost no risk of side effects. We believe that we can 
potentially achieve significant sales through our distributors as well 
as sales continuity as they use and order the product monthly," he 
concluded.<br />

<strong><strong>About Nutra Pharma Corp.</strong> </strong><br />

Nutra Pharma Corporation operates as a biotechnology company 
specializing in the acquisition, licensing, and commercialization of 
pharmaceutical products and technologies for the management of 
neurological disorders, cancer, autoimmune, and infectious diseases, 
including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), 
Adrenomyeloneuropathy (AMN) and Pain. Additionally, the Company markets 
several drug products for sale for the treatment of pain under the 
brands Cobroxin(R) and Nyloxin(TM). For additional information about 
Nutra Pharma, visit: <a href="http://www.nutrapharma.com/" target="_top">http://www.NutraPharma.com</a><br />

SEC Disclaimer<br />

<em>This press release contains forward-looking statements. The words 
or phrases "would be," "will allow," "intends to," "will likely result,"
 "are expected to," "will continue," "is anticipated," "estimate," 
"project," or similar expressions are intended to identify 
"forward-looking statements." Actual results could differ materially 
from those projected in Nutra Pharma's ("the Company") business plan. 
The distribution of Nyloxin through TCN should not be construed as an 
indication in any way whatsoever of the future value of the Company's 
common stock or its financial value. The Company's filings may be 
accessed at the SEC's Edgar system at <a href="http://www.globenewswire.com/newsroom/ctr?d=10005898&l=8&a=www.sec.gov&u=http%3A%2F%2Fwww.sec.gov" target="_top">www.sec.gov</a>.
 Statements made herein are as of the date of this press release and 
should not be relied upon as of any subsequent date. The Company 
cautions readers not to place reliance on such statements. Unless 
otherwise required by applicable law, we do not undertake, and we 
specifically disclaim any obligation, to update any forward-looking 
statements to reflect occurrences, developments, unanticipated events or
 circumstances after the date of such statement.</em><br />
<br />
<em>For more detail visit <a href="http://finance.yahoo.com/news/nutra-pharma-begins-marketing-nyloxin-161950330.html" target="_blank">YAHOO NEWS</a></em>

Nutra Pharma Begins Marketing Nyloxin(TM) Through Direct Distributors

Nutra Pharma Announces the Direct Distribution of Their Nyloxin(TM) Line of Pain Relievers Through TCN, a Network of Distributors in More...

Text Cash Network (Get Paid to Receive SMS )

Nutra Pharma Begins Marketing Nyloxin(TM) Through Direct Distributors

Contact Form